| Contributors: |
Cortellini, A; Tabernero, J; Mukherjee, U; Salazar, R; Sureda, A; Maluquer, C; Ferrante, D; Bower, M; Sharkey, R; Mirallas, O; Plaja, A; Cucurull, M; Mesia, R; Dalla Pria, A; Newsom-Davis, T; Van Hemelrijck, M; Sita-Lumsden, A; Apthorp, E; Vincenzi, B; Di Fazio, G; Tonini, G; Pantano, F; Bertuzzi, A; Rossi, S; Brunet, J; Lambertini, M; Pedrazzoli, P; Biello, F; D'Avanzo, F; Lee, A; Shawe-Taylor, M; Rogers, L; Murphy, C; Cooper, L; Andaleeb, R; Khalique, S; Bawany, S; Ahmed, S; Carmona-Garcia, M; Fort-Culillas, R; Linan, R; Zoratto, F; Rizzo, G; Perachino, M; Doonga, K; Gaidano, G; Bruna, R; Patriarca, A; Martinez-Vila, C; Perez Criado, I; Giusti, R; Mazzoni, F; Antonuzzo, L; Santoro, A; Parisi, A; Queirolo, P; Aujayeb, A; Rimassa, L; Diamantis, N; Bertulli, R; Fulgenzi, C; D'Alessio, A; Ruiz-Camps, I; Saoudi-Gonzalez, N; Garcia Illescas, D; Medina, I; Fox, L; Gennari, A; Aguilar-Company, J; Pinato, D; Evans, J; Swallow, J; Hanbury, G; Chung, C; Patel, M; Dettorre, G; Belessiotis, K; Saorise, D; Jones, E; Moss, C; Russell, B; Townsend, S; Jackson, A; Loizidou, A; Piccart, M; Pommeret, F; Colomba-Blameble, E; Prat, A; Cruz, C; Reyes, R; Segui, E; Marco-Hernandez, J; Viladot, M; Harbeck, N; Wuerstlein, R; Henze, F; Mahner, S; Felip, E; Scotti, L; Marrari, A |
| Description: |
Background: COVID-19 sequelae can affect about 15% of patients with cancer who survive the acute phase of SARS-CoV-2 infection and can substantially impair their survival and continuity of oncological care. We aimed to investigate whether previous immunisation affects long-term sequelae in the context of evolving variants of concern of SARS-CoV-2. Methods: OnCovid is an active registry that includes patients aged 18 years or older from 37 institutions across Belgium, France, Germany, Italy, Spain, and the UK with a laboratory-confirmed diagnosis of COVID-19 and a history of solid or haematological malignancy, either active or in remission, followed up from COVID-19 diagnosis until death. We evaluated the prevalence of COVID-19 sequelae in patients who survived COVID-19 and underwent a formal clinical reassessment, categorising infection according to the date of diagnosis as the omicron (B.1.1.529) phase from Dec 15, 2021, to Jan 31, 2022; the alpha (B.1.1.7)–delta (B.1.617.2) phase from Dec 1, 2020, to Dec 14, 2021; and the pre-vaccination phase from Feb 27 to Nov 30, 2020. The prevalence of overall COVID-19 sequelae was compared according to SARS-CoV-2 immunisation status and in relation to post-COVID-19 survival and resumption of systemic anticancer therapy. This study is registered with ClinicalTrials.gov, NCT04393974. Findings: At the follow-up update on June 20, 2022, 1909 eligible patients, evaluated after a median of 39 days (IQR 24–68) from COVID-19 diagnosis, were included (964 [50·7%] of 1902 patients with sex data were female and 938 [49·3%] were male). Overall, 317 (16·6%; 95% CI 14·8–18·5) of 1909 patients had at least one sequela from COVID-19 at the first oncological reassessment. The prevalence of COVID-19 sequelae was highest in the pre-vaccination phase (191 [19·1%; 95% CI 16·4–22·0] of 1000 patients). The prevalence was similar in the alpha–delta phase (110 [16·8%; 13·8–20·3] of 653 patients, p=0·24), but significantly lower in the omicron phase (16 [6·2%; 3·5–10·2] of 256 patients, ... |